Ziftomenib
Last Updated: 06/30/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 40 publications
Emerging drug profile: menin inhibitors in NPM1-mutated and KM2A-rearranged acute myeloid leukemia.
Journal: Leukemia & lymphoma
Published: May 27, 2026
Combined Menin and XPO1 inhibition drive synergistic antileukemic activity in KMT2A r and NPM1 -m AML.
Journal: bioRxiv : the preprint server for biology
Published: April 10, 2026
Ziftomenib (Komzifti) for acute myeloid leukemia.
Journal: The Medical letter on drugs and therapeutics
Published: March 07, 2026
Differentiation therapy in acute myeloid leukaemia: molecular basis, clinical progress, and future perspectives.
Journal: Frontiers in medicine
Published: February 26, 2026
Targeted Therapy in Acute Myeloid Leukemia: Current Approaches and Novel Directions.
Journal: Journal of personalized medicine
Published: February 16, 2026
Targeting the Menin-KMT2A Axis in Acute Leukemia: From Epigenetic Dependency to Clinical Translation.
Journal: European journal of haematology
Published: January 29, 2026
Menin Inhibition in Acute Myeloid MLL Rearranged Leukemias: A New Target for Precision Care.
Journal: Cancers
Published: January 20, 2026
Clinical research progress of menin inhibitors for acute myeloid leukemia: latest updates from the 2025 ASH Annual Meeting.
Journal: Experimental hematology & oncology
Published: January 08, 2026
Last Updated: 06/30/2026